Ionis Pharmaceuticals, Inc. (IONS)

NASDAQ: IONS · Real-Time Price · USD

69.97

-0.30 (-0.43%)

At close: Oct 10, 2025, 4:00 PM EDT

70.42

+0.45 (0.64%)

After-hours: Oct 10, 2025, 7:59 PM EDT

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
SPINRAZA Royalties Revenue	223.20M	216.10M	Log In	Log In	Log In	Upgrade
WAINUA Royalties Revenue	35.10M	20.20M	Log In	Log In	Log In	Upgrade
TEGSEDI and WAYLIVRA Revenue	37.70M	34.20M	Log In	Log In	Log In	Upgrade
Commercial Licensing and Other Royalty Revenue	44.50M	22.60M	Log In	Log In	Log In	Upgrade
Total Commercial Revenue	340.50M	293.10M	Log In	Log In	Log In	Upgrade
Amortization from Upfront Payments Revenue	-	131.40M	Log In	Log In	Log In	Upgrade
Milestone Payments Revenue	-	106.40M	Log In	Log In	Log In	Upgrade
R&D License Fees Revenue	-	71.30M	Log In	Log In	Log In	Upgrade
Other R&D Services Revenue	-	23.50M	Log In	Log In	Log In	Upgrade
Collaborative Agreement Revenue	523.50M	332.60M	Log In	Log In	Log In	Upgrade
Eplontersen Joint Development Revenue	79.90M	79.40M	Log In	Log In	Log In	Upgrade
Total R&D Revenue	603.40M	412.00M	Log In	Log In	Log In	Upgrade
Revenue (Other)	-638.35M	-432.16M	Log In	Log In	Log In	Upgrade
Revenue (Total)	944.05M	705.14M	Log In	Log In	Log In	Upgrade

Updated Jul 30, 2025. Data Source: Fiscal.ai.